Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632801 | 0.84 | CYP11B1 (0.41) | SMN1; SMN2MAPTRAB9AMEN1KMT2A | |
| SCHEMBL38660536 | 0.84 | CYP11B1 (0.41) | SMN1; SMN2MAPTRAB9AMEN1KMT2A | |
| SCHEMBL25348245 | 0.74 | SMARCA2 (0.46) | RAB9ANPC1ALDH1A1TP53TDP1 | |
| SCHEMBL30041002 | 0.74 | PARP10 (0.55) | — | |
| SCHEMBL27157851 | 0.74 | PARP10 (0.55) | — | |
| SCHEMBL31218502 | 0.71 | USP7 (0.58) | SMN1; SMN2MAPTRAB9AMEN1KMT2A | |
| SCHEMBL25346565 | 0.71 | USP7 (0.58) | SMN1; SMN2MAPTRAB9AMEN1KMT2A | |
| SCHEMBL22632800 | 0.71 | DHFR (0.51) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL29414855 | 0.71 | DHFR (0.51) | SMN1; SMN2MAPTRAB9ANPC1ALDH1A1 | |
| SCHEMBL531767 | 0.71 | SMARCA2 (0.66) | SMN1; SMN2MEN1KMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114096531-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227549-A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | SMN1; SMN2 2954/4885MAPT 1399/4885RAB9A 2397/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | SMN1; SMN2 2475/4885MAPT 1383/4885RAB9A 2635/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | SMN1; SMN2 2954/4885MAPT 1399/4885RAB9A 2397/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | SMN1; SMN2 3041/4885MAPT 1243/4885RAB9A 2240/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | SMN1; SMN2 3041/4885MAPT 1243/4885RAB9A 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.